Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

May 23, 2024

Study Completion Date

May 23, 2024

Conditions
Resistant Hypertension
Interventions
DRUG

Spironolactone

After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.

DRUG

Amiloride

After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.

Trial Locations (1)

Unknown

Severance Cardiovascular Hospital, Yonsei University Health System, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT04331691 - Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension | Biotech Hunter | Biotech Hunter